NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Portfolio Pulse from
Natera, Inc. (NASDAQ: NTRA) has commented on the NCCN's updated guidelines, which now include circulating tumor DNA (ctDNA) as a high-risk factor for recurrence in colon cancer, rectal cancer, and Merkel cell carcinoma. This update could impact Natera's business as a leader in cell-free DNA and genetic testing.
February 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera, Inc. is likely to benefit from the NCCN's updated guidelines that include ctDNA as a high-risk factor for cancer recurrence, potentially increasing demand for its genetic testing services.
The inclusion of ctDNA as a high-risk factor in NCCN guidelines could lead to increased adoption of Natera's testing services, as they are a leader in this field. This is likely to positively impact Natera's business and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90